PubRank

Curtis L Cooper

Author PubWeight™ 31.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011 4.68
2 Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda. BMJ 2009 1.98
3 Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007 1.85
4 Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda. J Int AIDS Soc 2011 1.46
5 Bipolar patients can safely and successfully receive interferon-based hepatitis C antiviral treatment. Eur J Gastroenterol Hepatol 2012 1.43
6 Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda. AIDS 2008 1.35
7 Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response. Vaccine 2004 1.23
8 Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. AIDS 2011 1.16
9 Applying a system approach to forecast the total hepatitis C virus-infected population size: model validation using US data. Liver Int 2011 1.06
10 Development and validation of the HIV Medication Readiness Scale. Assessment 2007 0.97
11 Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2012 0.97
12 Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008 0.94
13 Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol 2011 0.93
14 Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. Clin Exp Gastroenterol 2012 0.93
15 Bed utilization of patients with methicillin-resistant Staphylococcus aureus in a Canadian tertiary-care center. Infect Control Hosp Epidemiol 2002 0.89
16 Increasing public awareness about hepatitis C: development and validation of the brief hepatitis C knowledge scale. Scand J Caring Sci 2009 0.89
17 Evaluation of oral cannabinoid-containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008 0.88
18 Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients. Patient Prefer Adherence 2010 0.85
19 Cohort profile: the TASO-CAN Cohort Collaboration. Int J Epidemiol 2011 0.85
20 Interpreting discordant indirect and multiple treatment comparison meta-analyses: an evaluation of direct acting antivirals for chronic hepatitis C infection. Clin Epidemiol 2013 0.80
21 Influence of female sex on hepatitis C virus infection progression and treatment outcomes. Eur J Gastroenterol Hepatol 2016 0.79
22 Erythropoiesis-stimulating agent use for anemia induced by interferon-ribavirin treatment in patients with hepatitis C virus infection is not associated with increased rates of cardiovascular disease, thrombosis, malignancy, or death. Clin Infect Dis 2008 0.79
23 Transient elastography, APRI, and ultrasound have minimal utility in chronic low-replicative hepatitis B infection. Eur J Gastroenterol Hepatol 2014 0.79
24 Parasitic disease screening among HIV patients from endemic countries in a Toronto clinic. Can J Infect Dis Med Microbiol 2012 0.79
25 Analytical and biological variables influencing quantitative hepatitis C virus (HCV) measurement in HIV-HCV coinfection. Can J Gastroenterol 2006 0.75
26 De-"Liver"-ing HIV/hepatitis C virus-coinfected patients from antiretroviral hepatotoxicity. J Infect Dis 2007 0.75
27 Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review. Open Med 2009 0.75
28 Effect of high-dose vitamin C on hepatic cytochrome P450 3A4 activity. Pharmacotherapy 2005 0.75
29 Liver enzyme normalization predicts success of Hepatitis C oral direct-acting antiviral treatment. Clin Invest Med 2017 0.75
30 Hepatitis C antiviral treatment outcomes are comparable between clinical trial participants and recipients of standard-of-care therapy: an analysis of trial effect. Eur J Gastroenterol Hepatol 2013 0.75
31 Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Ann Hepatol 2011 0.75
32 Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol 2010 0.75
33 Influenza vaccination with 1/10th the full dose. N Engl J Med 2004 0.75
34 Successes in the HIV epidemic response in Africa: maintaining momentum in uncertain times. Int J Infect Dis 2010 0.75